The setbacks encountered in late-stage clinical trials of early DLL3-targeted therapies underscore the necessity for a more nuanced understanding of DLL3 biology within the intricate tapestry of SCLC pathogenesis. Here, DLL3 is linked to small cell lung carcinoma.